Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study
Kamal S. Pohar(The Ohio State University), Siamak Daneshmand(Unknown), Tracy M. Downs(University of Wisconsin–Madison), Joel DeCastro(Columbia University Irving Medical Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Yair Lotan(Southwestern Medical Center), Gary D. Steinberg(Rush University Medical Center), William C. Huang(NYU Langone Health), Badrinath R. Konety(Allina Health), Michael Woods(University of Cambridge), Sanjay Patel(Oklahoma City University), Trinity J. Bivalacqua(University of Pennsylvania), Jennifer M. Taylor(Michael E. DeBakey VA Medical Center), Jeffrey A. Jones(Cleveland Clinic), Mark Schoenberg(Montefiore Medical Center), J. Stephen Jones(Cleveland Clinic), Edouard J. Trabulsi(Thomas Jefferson University), Matthew J. Resnick(Vanderbilt University Medical Center), Michael A. O’Donnell(University of Iowa Health Care)
Cited by 8
Related Papers
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603